FDA Limits Usage Of New Alzheimer’s Medication

The Washington Post reports:

The Food and Drug Administration on Thursday limited the recommended use of a controversial new Alzheimer’s drug to patients with mild cognitive impairment or early dementia from the disease — a major change from the original label that included everyone with the illness.

The revised label clarifies that the drug, called Aduhelm, is intended for patients with early-stage disease — the population that participated in clinical trials of the drug, according to statements from the FDA and Biogen, the drug’s manufacturer.

The drug was approved June 7 — the first Alzheimer’s medication cleared since 2003 — sparking heated debates about whether it slows cognitive decline, as it was intended to do.

Read the full article.

FDA narrows use of controversial Alzheimer’s drug to patients with early-stage disease. The latest on the neverending debate over the new treatment. https://t.co/3JBZMlD2lG

— Laurie McGinley (@lauriemcginley2) July 8, 2021